Literature DB >> 22336245

Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.

Kwakye Peprah1, Xue Y Zhu, Suresh V K Eyunni, Jagan R Etukala, Vincent Setola, Bryan L Roth, Seth Y Ablordeppey.   

Abstract

Structure-activity relationship studies on 4-(4-(4-chlorophenyl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl)butan-1-one (SYA 013), a homopiperazine analog of haloperidol has resulted in an understanding of the effect of structural modifications on binding affinity at dopamine and serotonin receptor subtypes. Further exploration, using bioisosteric replacement strategies has led to the identification of several new agents including compounds 7, 8, 11 and 12 which satisfy the initial criteria for further exploration as new antipsychotic agents. In addition, compound 18, a D(3) selective tropanol, has been identified as having the potential for further optimization into a useful drug which may combat neuropsychiatric diseases. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336245      PMCID: PMC3356581          DOI: 10.1016/j.bmc.2012.01.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  16 in total

1.  Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.

Authors:  Seth Y Ablordeppey; Margaret Lyles-Eggleston; Barbara Bricker; Wang Zhang; Xue Zhu; Carl Goodman; Bryan L Roth
Journal:  Bioorg Med Chem Lett       Date:  2006-04-18       Impact factor: 2.823

2.  Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.

Authors:  M Lyles-Eggleston; R Altundas; J Xia; D M N Sikazwe; P Fan; Q Yang; S Li; W Zhang; X Zhu; A W Schmidt; M Vanase-Frawley; A Shrihkande; A Villalobos; R F Borne; S Y Ablordeppey
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

Review 3.  The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

Authors:  Gavin P Reynolds; Matthew J Hill; Shona L Kirk
Journal:  J Psychopharmacol       Date:  2006-07       Impact factor: 4.153

4.  From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

Authors:  Sangwon F Kim; Alex S Huang; Adele M Snowman; Cory Teuscher; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.

Authors:  E Raviña; I Casariego; C F Masaguer; J A Fontenla; G Y Montenegro; M E Rivas; M I Loza; M J Enguix; M Villazon; M I Cadavid; G C Demontis
Journal:  J Med Chem       Date:  2000-11-30       Impact factor: 7.446

6.  Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2011-12-22       Impact factor: 3.641

7.  H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

Authors:  Wesley K Kroeze; Sandra J Hufeisen; Beth A Popadak; Sean M Renock; SeAnna Steinberg; Paul Ernsberger; Karu Jayathilake; Herbert Y Meltzer; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2003-03       Impact factor: 7.853

8.  Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors.

Authors:  Donald M N Sikazwe; Shouming Li; Leroy Mardenborough; Vivian Cody; Brian L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem Lett       Date:  2004-12-06       Impact factor: 2.823

9.  The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+.

Authors:  Donald M N Sikazwe; Shouming Li; Margaret Lyles-Eggleston; Seth Y Ablordeppey
Journal:  Bioorg Med Chem Lett       Date:  2003-11-03       Impact factor: 2.823

10.  Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Authors:  David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard Mailman
Journal:  Neuropsychopharmacology       Date:  2003-05-21       Impact factor: 7.853

View more
  12 in total

1.  SYA 013 analogs as moderately selective sigma-2 (σ2) ligands: Structure-affinity relationship studies.

Authors:  Lamya Al-Ghanim; Xue Y Zhu; Gladys Asong; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2019-01-31       Impact factor: 3.641

2.  New analogs of SYA013 as sigma-2 ligands with anticancer activity.

Authors:  Gladys Asong; Xue Y Zhu; Barbara Bricker; Terrick Andey; Felix Amissah; Nazarius Lamango; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2019-04-08       Impact factor: 3.641

3.  Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.

Authors:  Xue Y Zhu; Jagan R Etukala; Suresh V K Eyunni; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Eur J Med Chem       Date:  2012-04-04       Impact factor: 6.514

4.  Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.

Authors:  Edward Ofori; Xue Y Zhu; Jagan R Etukala; Barbara A Bricker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-09-10       Impact factor: 3.641

5.  Identification of a new selective dopamine D4 receptor ligand.

Authors:  Dinithia Sampson; Xue Y Zhu; Suresh V K Eyunni; Jagan R Etukala; Edward Ofori; Barbara Bricker; Nazarius S Lamango; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2014-04-20       Impact factor: 3.641

6.  Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.

Authors:  Jagan R Etukala; Xue Y Zhu; Suresh V K Eyunni; Edem K Onyameh; Edward Ofori; Barbara A Bricker; Hye J Kang; Xi-Ping Huang; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-06-04       Impact factor: 3.641

7.  Further evaluation of the tropane analogs of haloperidol.

Authors:  Dinithia Sampson; Barbara Bricker; Xue Y Zhu; Kwakye Peprah; Nazarius S Lamango; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem Lett       Date:  2014-07-14       Impact factor: 2.823

8.  Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.

Authors:  Edward Ofori; Xue Y Zhu; Jagan R Etukala; Kwakye Peprah; Kamanski R Jordan; Adia A Adkins; Barbara A Bricker; Hye J Kang; Xi-Ping Huang; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-05-27       Impact factor: 3.641

9.  New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.

Authors:  Edward Ofori; Edem K Onyameh; Uma M Gonela; Chandrashekhar Voshavar; Barbara Bricker; Tracy L Swanson; Amy J Eshleman; Jennifer L Schmachtenberg; Shelley H Bloom; Aaron J Janowsky; Seth Y Ablordeppey
Journal:  Eur J Med Chem       Date:  2021-02-03       Impact factor: 6.514

10.  A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?

Authors:  Edem K Onyameh; Barbara A Bricker; Suresh V K Eyunni; Chandrashekhar Voshavar; Uma M Gonela; Edward Ofori; Andrea Jenkins; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2020-12-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.